Influence of dasatinib treatment on body height in children with acute myeloid leukemia
作者： Fang-Yuan Zheng , Le-Ping Zhang , Yue-Ping Jia , Jun Wu , Ai-Dong Lu
DOI: 10.7499/J.ISSN.1008-8830.2020.01.010
关键词: Pharmacotherapy 、 Myeloid 、 Dasatinib 、 Myeloid leukemia 、 Leukemia 、 Chemotherapy 、 Oncology 、 Tyrosine-kinase inhibitor 、 Internal medicine 、 Retrospective cohort study 、 Medicine
摘要: OBJECTIVE To study the influence of dasatinib treatment on body height in children with acute myeloid leukemia (AML). METHODS A retrospective analysis was performed for clinical data 86 AML aged <17 years. According to regimen, these were divided into a conventional chemotherapy group and group. The 57 given drugs without tyrosine kinase inhibitor, 29 dasatinib. two groups compared terms standard deviation score (HtSDS) at beginning after treatment, as well change HtSDS 1 2 years treatment. RESULTS There no significant difference between before Within first had similar trend Four reached final adult during follow-up, which significantly lower than target (P=0.044). In group, there height. adolescence (P=0.032). CONCLUSIONS Dasatinib may affect AML, use lead growth disorder, but has little effect short-term
sci-hub.st 参考文章(26)
Maynika V. Rastogi, Linda Stork, Brian Druker, Carolyn Blasdel, Thuan Nguyen, Bruce A. Boston, Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia Pediatric Blood & Cancer. ,vol. 59, pp. 840- 845 ,(2012) , 10.1002/PBC.24121
L. Kebapcilar, O. Bilgir, I. Alacacioglu, B. Payzin, F. Bilgir, P. Oner, I. Sari, M. Calan, O. Binicier, Does imatinib mesylate therapy cause growth hormone deficiency Medical Principles and Practice. ,vol. 18, pp. 360- 363 ,(2009) , 10.1159/000226288
Karthik R. Narayanan, Deepak Bansal, Rama Walia, Naresh Sachdeva, Anil Bhansali, Neelam Varma, R.K. Marwaha, Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis. Pediatric Blood & Cancer. ,vol. 60, pp. 1148- 1153 ,(2013) , 10.1002/PBC.24397
F Isfan, J Kanold, E Merlin, A Contet, N Sirvent, E Rochette, M Poiree, D Terral, H Carla-Malpuech, R Reynaud, B Pereira, P Chastagner, M C Simeoni, P Auquier, G Michel, F Deméocq, Growth hormone treatment impact on growth rate and final height of patients who received HSCT with TBI or/and cranial irradiation in childhood: a report from the French Leukaemia Long-Term Follow-Up Study (LEA) Bone Marrow Transplantation. ,vol. 47, pp. 684- 693 ,(2012) , 10.1038/BMT.2011.139
Frédéric Millot, Joelle Guilhot, André Baruchel, Arnaud Petit, Thierry Leblanc, Yves Bertrand, Françoise Mazingue, Patrick Lutz, Cecile Vérité, Christian Berthou, Claire Galambrun, Nicolas Sirvent, Karima Yacouben, Pascal Chastagner, Virginie Gandemer, Yves Reguerre, Gérard Couillault, Tackwa Khalifeh, Fanny Rialland, Growth deceleration in children treated with imatinib for chronic myeloid leukaemia. European Journal of Cancer. ,vol. 50, pp. 3206- 3211 ,(2014) , 10.1016/J.EJCA.2014.10.007
Haruko Shima, Mika Tokuyama, Akihiko Tanizawa, Chikako Tono, Kazuko Hamamoto, Hideki Muramatsu, Akihiro Watanabe, Noriko Hotta, Masaki Ito, Hidemitsu Kurosawa, Koji Kato, Masahito Tsurusawa, Keizo Horibe, Hiroyuki Shimada, Distinct Impact of Imatinib on Growth at Prepubertal and Pubertal Ages of Children with Chronic Myeloid Leukemia The Journal of Pediatrics. ,vol. 159, pp. 676- 681 ,(2011) , 10.1016/J.JPEDS.2011.03.046
Deepak Bansal, Upender Shava, Neelam Varma, Amita Trehan, R.K. Marwaha, Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatric Blood & Cancer. ,vol. 59, pp. 481- 484 ,(2012) , 10.1002/PBC.23389
A. Ulmer, J. Tabea Tauer, I. Glauche, R. Jung, M. Suttorp, TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model. Klinische Padiatrie. ,vol. 225, pp. 120- 126 ,(2013) , 10.1055/S-0033-1343483
Bernadette Anna Sophia Jaeger, Josephine Tabea Tauer, Anna Ulmer, Eberhard Kuhlisch, Heinz Juergen Roth, Meinolf Suttorp, Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment Medical Science Monitor. ,vol. 18, ,(2012) , 10.12659/MSM.883599
Kimbach Carpiuc, Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics OncoTargets and Therapy. ,vol. 3, pp. 205- 210 ,(2010) , 10.2147/OTT.S13052